These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 18948147)

  • 1. Lysosomal involvement in cell death and cancer.
    Kirkegaard T; Jäättelä M
    Biochim Biophys Acta; 2009 Apr; 1793(4):746-54. PubMed ID: 18948147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysosomal cysteine peptidases - Molecules signaling tumor cell death and survival.
    Pišlar A; Perišić Nanut M; Kos J
    Semin Cancer Biol; 2015 Dec; 35():168-79. PubMed ID: 26255843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lysosomes as targets for cancer therapy.
    Fehrenbacher N; Jäättelä M
    Cancer Res; 2005 Apr; 65(8):2993-5. PubMed ID: 15833821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sphingolipid rheostat alterations related to transformation can be exploited for specific induction of lysosomal cell death in murine and human glioma.
    Mora R; Dokic I; Kees T; Hüber CM; Keitel D; Geibig R; Brügge B; Zentgraf H; Brady NR; Régnier-Vigouroux A
    Glia; 2010 Aug; 58(11):1364-83. PubMed ID: 20607862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Typical and Atypical Inducers of Lysosomal Cell Death: A Promising Anticancer Strategy.
    Domagala A; Fidyt K; Bobrowicz M; Stachura J; Szczygiel K; Firczuk M
    Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30071644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Lysosomal cysteine proteinases at neoplastic transformation].
    Dilakian EA; Tsvetkova IV
    Biomed Khim; 2005; 51(5):485-500. PubMed ID: 16342665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysosomal and prostasomal hydrolytic enzymes and redox processes and initiation of prostate cancer.
    Tappel A
    Med Hypotheses; 2005; 64(6):1170-2. PubMed ID: 15823710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysosomes and lysosomal cathepsins in cell death.
    Repnik U; Stoka V; Turk V; Turk B
    Biochim Biophys Acta; 2012 Jan; 1824(1):22-33. PubMed ID: 21914490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lysosomal-mitochondrial cross-talk during cell death.
    Repnik U; Turk B
    Mitochondrion; 2010 Nov; 10(6):662-9. PubMed ID: 20696281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysosomes and autophagy in cell death control.
    Kroemer G; Jäättelä M
    Nat Rev Cancer; 2005 Nov; 5(11):886-97. PubMed ID: 16239905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitization to the lysosomal cell death pathway by oncogene-induced down-regulation of lysosome-associated membrane proteins 1 and 2.
    Fehrenbacher N; Bastholm L; Kirkegaard-Sørensen T; Rafn B; Bøttzauw T; Nielsen C; Weber E; Shirasawa S; Kallunki T; Jäättelä M
    Cancer Res; 2008 Aug; 68(16):6623-33. PubMed ID: 18701486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysosomes and lysosomal proteins in cancer cell death (new players of an old struggle).
    Tardy C; Codogno P; Autefage H; Levade T; Andrieu-Abadie N
    Biochim Biophys Acta; 2006 Apr; 1765(2):101-25. PubMed ID: 16412578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer-associated lysosomal changes: friends or foes?
    Kallunki T; Olsen OD; Jäättelä M
    Oncogene; 2013 Apr; 32(16):1995-2004. PubMed ID: 22777359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Destination 'lysosome': a target organelle for tumour cell killing?
    Castino R; Démoz M; Isidoro C
    J Mol Recognit; 2003; 16(5):337-48. PubMed ID: 14523947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The causes of cancer revisited: "mitochondrial malignancy" and ROS-induced oncogenic transformation - why mitochondria are targets for cancer therapy.
    Ralph SJ; Rodríguez-Enríquez S; Neuzil J; Saavedra E; Moreno-Sánchez R
    Mol Aspects Med; 2010 Apr; 31(2):145-70. PubMed ID: 20206201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lysosomal pathways to cell death and their therapeutic applications.
    Česen MH; Pegan K; Spes A; Turk B
    Exp Cell Res; 2012 Jul; 318(11):1245-51. PubMed ID: 22465226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The secretion of lysosomal enzymes.
    Davies P; Allison AC
    Front Biol; 1976; 45():61-98. PubMed ID: 185100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitization to the lysosomal cell death pathway upon immortalization and transformation.
    Fehrenbacher N; Gyrd-Hansen M; Poulsen B; Felbor U; Kallunki T; Boes M; Weber E; Leist M; Jäättelä M
    Cancer Res; 2004 Aug; 64(15):5301-10. PubMed ID: 15289336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combating apoptosis and multidrug resistant cancers by targeting lysosomes.
    Groth-Pedersen L; Jäättelä M
    Cancer Lett; 2013 May; 332(2):265-74. PubMed ID: 20598437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysosomal iron, iron chelation, and cell death.
    Terman A; Kurz T
    Antioxid Redox Signal; 2013 Mar; 18(8):888-98. PubMed ID: 22909065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.